• Early Diagnosis and Recurrence Monitoring of Colorectal Cancer

  NCT06991452

  Not yet recruitingObservationalUpdated May 28, 2025
• Multiple Screening Methods for the Detection of Chinese Colorectal Advanced Adenomatous Polyps and Cancer

  NCT03411707

  Unknown statusObservationalUpdated May 6, 2022
• Development of a Pan-Cancer Screening Model Based on Blood Biomarkers

  NCT07554157

  Active, not recruitingObservationalUpdated Apr 28, 2026
• External, Multicentre Validation of a Machine-Learning Model to Predict Colonic Adenoma in Indian Adults

  NCT07329816

  Not yet recruitingObservationalUpdated Jan 12, 2026
• Study on the Diagnostic Value of Multi-omics Combined Detection for Precancerous Lesions of CRC

  NCT05530746

  Unknown statusObservationalUpdated Sep 7, 2022
• Multi-omics Study for Early Detection of Colorectal Cancer (MOED-CRC)

  NCT06220617

  RecruitingObservationalUpdated Jan 30, 2024

ClinicalTrials.gov ID

NCT07692555

Lead Sponsor

Peking University Cancer Hospital & InstituteOTHER

Overall Status

Not yet recruiting

Study Type

Observational

Enrollment

20,000Estimated

Last Update Posted

Jul 23, 2026Actual

Start Date

Jul 15, 2026Estimated

Primary Completion Date

Jul 30, 2028Estimated

Completion Date

Jul 1, 2029Estimated

Official Title

Development and Validation of a Colorectal Cancer Diagnostic Model: A Multicenter Study in China (CCDM-CN)

Brief Summary

This is a multicenter, observational study designed to develop and validate a diagnostic model for colorectal cancer and advanced colorectal neoplasia among adults undergoing routine-care colonoscopy in the Chinese population.

The study will enroll adults aged 18 to 80 years who have already been scheduled or planned to undergo colonoscopy according to routine clinical care, physical examination, or screening pathways at participating medical institutions. The study will not invite, organize, require, or otherwise arrange colonoscopy for any participant. Colonoscopy, bowel preparation, anesthesia assessment, biopsy, pathology examination, and subsequent clinical management will be performed solely according to the existing clinical pathway of each participating institution.

After informed consent, participants will be invited to complete a standardized electronic questionnaire before their scheduled colonoscopy. The questionnaire will collect self-reported information on demographic characteristics, lifestyle factors, environmental exposures, personal medical history, family history of colorectal cancer, prior colonoscopy history, and gastrointestinal symptoms. The study team will also abstract colonoscopy and pathology results from medical records. No additional biological specimens will be collected for research purposes.

The primary clinical outcome is prevalent colorectal advanced neoplasia, defined as colorectal cancer, advanced colorectal adenoma, or advanced colorectal serrated lesion identified through colonoscopy and associated pathology. Statistical and machine-learning approaches will be used to develop and validate diagnostic models. Model performance will be evaluated by discrimination, calibration, and clinical net benefit in internal validation and multicenter external validation.

Detailed Description

Colorectal cancer imposes a heavy disease burden in China. Early detection of colorectal cancer and advanced precancerous lesions can improve clinical outcomes and reduce colorectal cancer mortality. However, colonoscopy, the standard method for screening, is invasive and resource-intensive. A practical, accurate, and clinically applicable risk prediction model may help identify individuals with a higher probability of prevalent colorectal cancer or advanced colorectal neoplasia, support risk-adapted early detection strategies, and optimize resource utilization. Yet existing diagnostic and risk prediction tools have been developed primarily in Western populations and demonstrate limited applicability to Chinese individuals.

This study is designed as a multicenter, observational, and cross-sectional study enrolling adults aged 18-80 years who are already scheduled to undergo colonoscopy during routine clinical care at participating hospitals. The study does not assign participants to any medical intervention and does not determine whether they should undergo colonoscopy. All decisions regarding the colonoscopy, including the timing, conduct of the procedure, pathology evaluation, and subsequent clinical care, are made by the treating clinicians following the routine clinical pathway of the respective participating institution.

After providing informed consent, eligible participants will complete a standardized electronic questionnaire before colonoscopy. The questionnaire will collect candidate predictors, including demographics, lifestyle and behavioral factors (e.g., smoking, alcohol consumption, physical activity, diet), personal and family medical history, and gastrointestinal symptoms. After the index clinical procedure, clinical colonoscopy and pathology reports will be abstracted. The main outcome is prevalent colorectal advanced neoplasia at the index colonoscopy, including colorectal carcinoma, advanced adenoma (adenoma ≥10 mm, or with high-grade dysplasia, or with villous/tubulovillous histology), and advanced serrated adenoma (traditional serrated adenoma or sessile serrated adenoma ≥10 mm or with high-grade dysplasia).

At least 20,000 participants will be enrolled across multiple sites, including Peking University Cancer Hospital & Institute, the First Affiliated Hospital of Xiamen University, Fujian Provincial Hospital, Ningxia Hui Autonomous Region People's Hospital, and other collaborating institutions. Participants are enrolled competitively until the total sample size is reached.

The sample size was determined to support the development and validation of a multivariable risk prediction model, following the framework proposed by Riley et al. We adopted a conservative set of assumptions, with an expected prevalence of advanced colorectal neoplasia of approximately 6%, an anticipated model discrimination (AUC) in the range of 0.65 to 0.70, and approximately 40 candidate predictor parameters covering demographics, lifestyle factors, personal and family medical history, prior colonoscopy history, and gastrointestinal symptoms. The minimum sample size required for model development is estimated at 9,000 to 13,500 participants. After reserving 20% to 30% of enrolled participants for internal validation, the total required sample size increases to approximately 11,000 to 19,000. To further accommodate potential incomplete data, non-evaluable outcomes, and multi-center external validation, the final enrollment target was set at a minimum of 20,000 participants.

Candidate prediction models will be developed using logistic regression and machine-learning algorithms. Internal validation will be performed using cross-validation and bootstrap methods. External validation will be performed across participating centers. Model performance will be assessed using the area under the receiver operating characteristic curve, calibration measures, and decision-curve analysis. The final model and risk stratification scheme will be selected based on predictive performance, stability, interpretability, feasibility, and data-collection burden. This scheme will then be translated into a practical tool for clinical and public health settings to guide individualized colorectal cancer screening strategies.

• Colorectal Cancer
• Advanced Neoplasia
• Prediction Models
• Risk Stratification
• Precision Screening

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

Yes

Eligibility Criteria

Inclusion Criteria:

• Age between 18 and 80 years at the time of enrollment.
• Already scheduled to undergo colonoscopy according to routine clinical care, physical examination, or screening pathways at a participating medical institution.
• No prior history of colorectal cancer or advanced colorectal neoplasia.
• No contraindications to colonoscopy (as determined by the treating physician).
• Able to understand the study information and complete the colorectal cancer risk-factor questionnaire independently or with appropriate assistance.
• Willing to provide informed consent for completion of the questionnaire and for collection of routine clinical colonoscopy, pathology, and related medical-record data.

Exclusion Criteria:

• The baseline colorectal cancer risk-factor questionnaire is not completed, or considered invalid because of substantial missing or inconsistent information.
• The scheduled index colonoscopy is cancelled, not performed, or not completed regardless of the underlying reason (e.g., inadequate bowel preparation).
• Incomplete or unavailable colonoscopy or pathology data after the procedure.
• Refusal or withdrawal of informed consent.

Observational Model

Other

Time Perspective

Cross-Sectional

Lead Sponsor

Peking University Cancer Hospital & InstituteOTHER

Collaborators

The First Affiliated Hospital of Xiamen UniversityOTHER

Fujian Provincial HospitalOTHER

People's Hospital of Ningxia Hui Autonomous RegionOTHER

fjzhengxl@163.com+86-0591-87557768